Form 4: Ligand Pharmaceuticals Significantly Increases Stake in Pelthos Therapeutics Following Strategic Merger and Stock Split

Ligand Pharmaceuticals Inc. has significantly increased its beneficial ownership in Pelthos Therapeutics Inc. through the acquisition of common stock and convertible preferred stock following a strategic merger and a 1-for-10 reverse stock split.

Summary

• Ligand Pharmaceuticals Inc. (Reporting Person) significantly increased its beneficial ownership in Pelthos Therapeutics Inc. (Issuer) on July 1, 2025.
• This increase includes the acquisition of 1,500,000 shares of Pelthos Therapeutics common stock at a price of $10 per share, resulting from the conversion of Series A Convertible Preferred Stock.
• Ligand also acquired 15,000 shares of Series A Convertible Preferred Stock through conversion, which yielded the 1,500,000 common shares.
• An additional 31,278.681 shares of Series A Convertible Preferred Stock were received in exchange for LNHC, Inc. common stock as part of a merger agreement dated April 16, 2025.
• Following these transactions, Ligand Pharmaceuticals Inc. beneficially owns 1,500,000 shares of common stock and a total of 37,278.681 shares of Series A Convertible Preferred Stock (3,000 from the conversion transaction and 34,278.681 from the merger transaction).
• The Series A convertible preferred stock is convertible at any time, has no expiration date, and is subject to a contractual limitation preventing beneficial ownership exceeding 49.9% of outstanding common stock after conversion.
• All reported numbers reflect a 1-for-10 reverse stock split effected by Pelthos Therapeutics Inc. on July 1, 2025.
• The merger involved CHRO Merger Sub, Inc. (a wholly-owned subsidiary of Pelthos) with LNHC, Inc. (a wholly-owned subsidiary of Ligand), with LNHC, Inc. continuing as a wholly-owned subsidiary of Pelthos.

Sentiment

Score: 8

Explanation: The filing indicates a significant strategic investment and merger activity, with Ligand Pharmaceuticals increasing its stake in Pelthos Therapeutics. This suggests a positive outlook from a major investor and potential for future growth or synergy resulting from the merger.

Positives

• Ligand Pharmaceuticals Inc. has significantly increased its strategic stake in Pelthos Therapeutics Inc., indicating confidence in the company's future and potential for synergy.
• The merger of LNHC, Inc. into Pelthos Therapeutics Inc. suggests a strategic consolidation or acquisition, potentially enhancing Pelthos's assets or capabilities.
• The acquisition of Series A Convertible Preferred Stock provides flexibility for Ligand to increase its common stock ownership in Pelthos over time, up to a 49.9% beneficial ownership cap.

Negatives

• The 1-for-10 reverse stock split effected by Pelthos Therapeutics Inc. on July 1, 2025, while a technical adjustment, can sometimes be perceived negatively by the market as it often occurs when a stock's price is low.

Risks

• The Series A convertible preferred stock is subject to a contractual limitation preventing the reporting person from converting shares if it would result in beneficial ownership exceeding 49.9% of the common stock outstanding.

Future Outlook

The Series A convertible preferred stock held by Ligand Pharmaceuticals Inc. is convertible at any time, providing a future option to increase common stock ownership in Pelthos Therapeutics Inc. up to a 49.9% beneficial ownership threshold.

Management Comments

• Octavio Espinoza, Chief Financial Officer of Ligand Pharmaceuticals Incorporated, signed the filing.

Industry Context

This transaction represents a strategic move within the biotechnology or pharmaceutical sector, where larger entities often acquire or invest in smaller companies to expand their pipelines or market reach. The merger structure suggests a consolidation play, common in industries focused on intellectual property and specialized assets.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• The transaction involves the merger of LNHC, Inc., a wholly-owned subsidiary of Ligand Pharmaceuticals Inc. (the reporting person), with CHRO Merger Sub, Inc., a wholly-owned subsidiary of Pelthos Therapeutics Inc. LNHC, Inc. became a wholly-owned subsidiary of Pelthos Therapeutics Inc. as a result of this merger.

Stakeholder Impact

• Shareholders of Pelthos Therapeutics Inc. may benefit from increased institutional ownership and potential strategic advantages arising from the merger, though the reverse stock split could influence per-share price perception.
• Shareholders of Ligand Pharmaceuticals Inc. gain a strategic investment in a potentially growing asset within the biotechnology sector.
• Employees of LNHC, Inc. are now part of a wholly-owned subsidiary of Pelthos Therapeutics Inc., which may lead to integration or operational adjustments.

Next Steps

• Potential future conversion of Series A Convertible Preferred Stock into common stock by Ligand Pharmaceuticals Inc., subject to the 49.9% beneficial ownership limitation.

Key Dates

Recommendation

Keywords

SEC Form 4, Beneficial Ownership, Stock Acquisition, Convertible Preferred Stock, Merger, Reverse Stock Split, Pelthos Therapeutics, Ligand Pharmaceuticals, Corporate Governance, Investment, Insider Transaction